Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia

Pituitary

Volumn 14, Issue 1, 2011, Pages 44-52

  Kleinberg, David L ^a,b   Ameri, Pietro ^a,b,c   Singh, Baljit ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Affairs Medical Center   (United States)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

IGF I inhibition; Mammary hyperplasia; Prevention of hyperplasia; SOM230; Tamoxifen

Indexed keywords

ESTRADIOL; GROWTH HORMONE; INSULIN RECEPTOR SUBSTRATE 1; OCTREOTIDE; PASIREOTIDE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CELL; BREAST HYPERPLASIA; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GROWTH HORMONE RELEASE; HYPOPHYSECTOMY; INHIBITION KINETICS; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; ESTRADIOL; FEMALE; GROWTH HORMONE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MAMMARY GLANDS, ANIMAL; RATS; SOMATOSTATIN; TAMOXIFEN;

EID: 79951958341     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-010-0257-0     Document Type: Article

References (37)

1. LC Hartmann TA Sellers MH Frost WL Lingle AC Degnim K Ghosh RA Vierkant SD Maloney VS Pankratz DW Hillman VJ Suman J Johnson C Blake T Tlsty CM Vachon LJ Melton III DW Visscher 2005 Benign breast disease and the risk of breast cancer N Engl J Med 353 229 237 1:CAS:528:DC%2BD2MXmt1KmsrY%3D 10.1056/NEJMoa044383 16034008 (Pubitemid 41058322)
2. B Fisher JP Costantino DL Wickerham RS Cecchini WM Cronin A Robidoux TB Bevers MT Kavanah JN Atkins RG Margolese CD Runowicz JM James LG Ford N Wolmark 2005 Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study J Natl Cancer Inst 97 1652 1662 1:CAS:528:DC%2BD2MXht1entb7L 10.1093/jnci/dji372 16288118 (Pubitemid 41672231)
3. R Day 2001 Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study National Surgical Adjuvant Breast and Bowel Project. Ann NY Acad Sci 949 143 150 1:CAS:528: DC%2BD38XnsFWruw%3D%3D (Pubitemid 34059970)
4. The BIG 1-98 Collaborative Group (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361:766-776
5. DL Kleinberg WF Ruan V Catanese CB Newman M Feldman 1990 Non-lactogenic effects of growth hormone on growth and insulin-like growth factor-I messenger ribonucleic acid of rat mammary gland Endocrinology 126 3274 3276 1:CAS:528:DyaK3cXksFakuro%3D 10.1210/endo-126-6-3274 2351118 (Pubitemid 20216594)
6. M Feldman WF Ruan BC Cunningham JA Wells DL Kleinberg 1993 Evidence that the growth hormone receptor mediates differentiation and development of the mammary gland Endocrinology 133 1602 1608 1:CAS:528:DyaK2cXpt1w%3D 10.1210/en.133.4.1602 8404600 (Pubitemid 23295185)
7. W Ruan CB Newman DL Kleinberg 1992 Intact and aminoterminally shortened forms of insulin-like growth factor I induce mammary gland differentiation and development Proc Natl Acad Sci USA 89 10872 10876 1:CAS:528:DyaK3sXjtlansw%3D%3D 10.1073/pnas.89.22.10872 1438291
8. W Ruan L Powell-Braxton JJ Kopchick DL Kleinberg 1999 Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development Endocrinology 140 1984 1989 1:CAS:528:DyaK1MXislSnsLw%3D 10.1210/en.140.5.1984 10218945 (Pubitemid 30639064)
9. W Ruan ME Monaco DL Kleinberg 2005 Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-I action Endocrinology 146 1170 1178 1:CAS:528:DC%2BD2MXitlehsbc%3D 10.1210/en.2004-1360 15604210 (Pubitemid 40289306)
10. Yee D, Chavez JB, Ruan WF, Kleinberg DL (2000) Proc of Am Soc Clin Oncology Meeting, Abstract 813
11. W Ruan F Fahlbusch DR Clemmons ME Monaco PD Walden A Silva HA Schmid DL Kleinberg 2006 SOM230 inhibits IGF-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3? Mol Endocrinol 20 426 436 1:CAS:528:DC%2BD28XhsVKmuro%3D 10.1210/me.2005-0283 16223973 (Pubitemid 43152515)
12. Novartis (2010) Clinical development SOM 230 Pasireotide s.c. and Pasireotide LAR Investigator's Brochure. Novartis Investigator's Brochure Edition 9
13. SE Kahn LJ Klaff MW Schwartx JC Beard RN Bergman GJ Taborsky Jr D Porte Jr 1990 Treatment with a somatostatin analog decreases pancreatic B-cell and whole body sensitivity go glucose J Clin Endocrinol Metab 71 994 1002 1:CAS:528:DyaK3MXhslOnsQ%3D%3D 10.1210/jcem-71-4-994 2205630
14. WD Dupont DL Page 1985 Risk factors for breast cancer in women with proliferative breast disease N Engl J Med 312 146 151 1:STN:280: DyaL2M%2Fos1Wguw%3D%3D 10.1056/NEJM198501173120303 3965932 (Pubitemid 15192861)
15. C Bodian KH Perzin R Lattes P Hoffman T Abernathy 1993 Prognostic significance of benign proliferative breast disease Cancer 71 3896 3907 1:STN:280:DyaK3s3osVGjsA%3D%3D 10.1002/1097-0142(19930615)71:12<3896::AID- CNCR2820711217>3.0.CO;2-I 8389654 (Pubitemid 23172967)
16. K Christov A Ikui A Shilkaitis A Green R Yao M You C Grubbs V Steele R Lubet IB Weinstein 2003 Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors Breast Cancer Res Treat 77 253 264 1:CAS:528:DC%2BD3sXivFWq 10.1023/A: 1021804121171 12602925 (Pubitemid 36197640)
17. NC Peterson MD Servinsky A Christian Z Peng W Qiu J Mann J Dicello DL Huso 2005 Tamoxifen resistance and Her2/neu expression in an aged, irradiated rat breast carcinoma model Carcinogenesis 26 1542 1552 1:CAS:528: DC%2BD2MXpsValtr8%3D 10.1093/carcin/bgi103 15860508 (Pubitemid 41236047)
18. SG Bonnette DL Hadsell 2001 Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds Endocrinology 142 4937 4945 1:CAS:528:DC%2BD3MXnslGqu7g%3D 10.1210/en.142.11.4937 11606462 (Pubitemid 33022370)
19. MA Guvakova E Surmacz 1997 Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells Cancer Res 57 2606 2610 1:CAS:528:DyaK2sXkt12qs7s%3D 9205064 (Pubitemid 27283767)
20. W Ruan V Catanese R Wieczorek M Feldman DL Kleinberg 1995 Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid Endocrinology 136 1296 1302 1:CAS:528:DyaK2MXjvFCjtb0%3D 10.1210/en.136.3.1296 7867584
21. W Ruan DL Kleinberg 1999 Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development Endocrinology 140 5075 5081 1:CAS:528:DyaK1MXmvFemtr8%3D 10.1210/en.140.11.5075 10537134
22. DL Hadsell G Abdel-Fattah 2001 Regulation of cell apoptosis by insulin-like growth factor I Adv Exp Med Biol 501 79 85 1:CAS:528: DC%2BD38XivFejurs%3D 11787734 (Pubitemid 34102181)
23. MA Stull AM Rowzee AV Loladze TL Wood 2004 Growth factor regulation of cell cycle progression in mammary epithelial cells J Mammary Gland Biol Neoplasia 9 15 26 10.1023/B:JOMG.0000023585.95430.f4 15082915 (Pubitemid 39137494)
24. C Bruns I Lewis U Briner G Meno-Tetang G Weckbecker 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile Eur J Endocrinol 146 707 716 1:CAS:528:DC%2BD38XktFGitr4%3D 10.1530/eje.0.1460707 11980628 (Pubitemid 34552506)
25. I Lewis W Bauer R Albert N Chandramouli J Pless G Weckbecker C Bruns 2003 A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential J Med Chem 46 2334 2344 1:CAS:528:DC%2BD3sXjs1WisL4%3D 10.1021/jm021093t 12773038 (Pubitemid 36637918)
26. HA Schmid P Schoeffter 2004 Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors Neuroendocrinology 80 Suppl 1 47 50 1:CAS:528:DC%2BD2cXotlahtb8%3D 10.1159/000080741 15477717 (Pubitemid 39382369)
27. K Sharma YC Patel CB Srikant 1996 Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3 Mol Endocrinol 10 1688 1696 1:CAS:528:DyaK28Xntlartrc%3D 10.1210/me.10.12.1688 8961277 (Pubitemid 26408756)
28. LJ Hofland 2003 Responsiveness to somatostatin analog treatment and potentials of novel somatostatin analog J Endocrinol Invest 26 8 13 1:STN:280:DC%2BD2czjtVyqug%3D%3D 15233204
29. RD Murray K Kim SG Ren M Chelly Y Umehara S Melmed 2004 Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis J Clin Invest 114 349 356 1:CAS:528:DC%2BD2cXmtlynsrg%3D 15286801 (Pubitemid 39071607)
30. RD Murray K Kim SG Ren I Lewis G Weckbecker C Bruns S Melmed 2004 The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion J Clin Endocrinol Metab 89 3027 3032 1:CAS:528: DC%2BD2cXmtlKjsLY%3D 10.1210/jc.2003-031319 15181094 (Pubitemid 38766404)
31. M Duran-Prado A Saveanu RM Luque MD Gahete F Gracia-Navarro P Jaquet H Dufour MM Malagon MD Culler A Barlier JP Castano 2010 A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs J Clin Endocrinol Metab 95 2497 2502 1:CAS:528:DC%2BC3cXmtFensb4%3D 10.1210/jc.2009-2247 20233783
32. AV Lee ST Taylor J Greenall JD Mills DW Tonge P Zhang J George ML Fiorotto DL Hadsell 2003 Rapid induction of IGF-IR signaling in normal and tumor tissue following intravenous injection of IGF-I in mice Horm Metab Res 35 651 655 1:CAS:528:DC%2BD2cXpvVygsQ%3D%3D 10.1055/s-2004-814141 14710342 (Pubitemid 38058167)
33. KB Horwitz WL McGuire 1978 Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor J Biol Chem 253 2223 2228 1:CAS:528:DyaE1cXhvVOlurc%3D 632265 (Pubitemid 8328205)
34. BM Arafah PM Gullino A Manni OH Pearson 1980 Effect of ovariectomy on hormone receptors and growth of N-nitrosomethylurea-induced mammary tumors in the rat Cancer Res 40 4628 4630 1:CAS:528:DyaL3MXlvFGiuw%3D%3D 6254648 (Pubitemid 11199730)
35. HJ Kim BC Litzenburger X Cui DA Delgado BC Grabiner X Lin MT Lewis MM Gottardis TW Wong RM Attar JM Carboni AV Lee 2007 Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail Mol Cell Biol 27 3165 3175 1:CAS:528:DC%2BD2sXkt1OgtbY%3D 10.1128/MCB.01315-06 17296734 (Pubitemid 46581327)
36. BC Litzenburger HJ Kim I Kuiatse JM Carboni RM Attar M Gottardis CR Fairchild AV Lee 2009 BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells Clin Cancer Res 15 226 237 1:CAS:528:DC%2BD1MXhs1ekuw%3D%3D 10.1158/1078-0432.CCR-08-0801 19118050
37. J van der Hoek AJ van der Lely R Feelders W Wouter W de Herder P Uitterlinden K Poon V Boerlin I Lewist T Krahnke L Hofland S Lamberts 2005 The Somatostatin analogue SOM 230 compared with octreotide, induces differential effects in several metabolic pathways in acromeglic patients Clin Endocrinol 63 176 184 10.1111/j.1365-2265.2005.02322.x (Pubitemid 41097986)